Isolated Metastasis of Uterine Leiomyosarcoma to the Small Bowel Diagnosed Initially as Uterine Leiomyoma: A Case Report and Review of the Literature

Semmar A1,*, Mouden K1, Laanaz S2, ELallam O1, Kabdani T1, Elkacemi T1, Majaoui SEL1 and Benjaafar N1

1Department of Radiotherapy, National Institute of Oncology, University Mohammed V, Rabat, Morocco
2Department of Medical Oncology, National Institute of Oncology, University Mohammed V, Rabat, Morocco

Abstract

Introduction: Uterine sarcoma is rare, Leiomyosarcoma is the main type of sarcoma that may resemble to leiomyoma. Metastasis to small bowel is extremely rare, treatment is chemotherapy and the prognosis is unfavorable.

Case presentation: A 41-year-old Moroccan women, with no significant past medical history, was diagnosed with intracavitary myoma. The patient underwent subtotal hysterectomy with bilateral salpingectomy. Pathology findings indicated high grade leiomyosarcoma. The patient was re-operated, she underwent bilateral oophorectomy, omentectomy, segmental small bowel resection and excision of uterine cervix. Histopathology revealed a metastatic lesion of the primary uterine leiomyosarcoma of the small bowel. The patient was treated by chemotherapy: Doxorubicin 75 mg/m2 every 3 weeks for 6 cycles. The follow-up of this patient is 10 months and her ECOG is 0.

Conclusion: Leiomyosarcoma is the main type of sarcoma that may resemble to leiomyoma. Metastasis to small bowel is rare, treatment is chemotherapy and the prognosis is poor.

Keywords: Uterine leiomyosarcoma; Small bowel; Surgery; Chemotherapy

Introduction

Uterine sarcoma is rare, Leiomyosarcoma is the main type of sarcoma that may resemble to leiomyoma. Lungs, liver, bones, and brain are the common sites of metastases through hematogenous dissemination [1]. Metastasis to small bowel is extremely rare, treatment is chemotherapy and the prognosis is unfavorable [2,3].

Case Report

A 41-year-old Moroccan women, with no significant past medical history, presented abdominal pain and uterine bleeding. Physical examination revealed an enlarged uterus. A pelvic ultrasound showed echogenic intracavitary myoma finely calcified measuring 5 × 6 × 7 cm. Preoperative Magnetic resonance imaging MRI was not realized. The patient was operated, she underwent subtotal hysterectomy with bilateral salpingectomy. Pathology findings indicated high grade leiomyosarcoma submucosal extensive and necrotic. Postoperative magnetic resonance imaging MRI of abdomen and pelvis revealed sequelae of subtotal hysterectomy with a cervix with a normal signal (Figure 1). Chest CT was normal. The patient was re-operated, she underwent bilateral oophorectomy, omentectomy, segmental small bowel resection the jejunum and excision of uterine cervix.

Histopathology revealed a metastatic lesion of the primary uterine leiomyosarcoma of the small bowel (Figure 2). It seems to be a metastasis and not direct extension. Chemotherapy treated the patient: Doxorubicin 75 mg/m2 every 3 weeks for 6 cycles. Follow-up of this patient is planned for every 3 months for 2 years, every 6 months for 3 years, and annually for life. Her follow-up is 10 months and her ECOG is 0.

Discussion

Benign uterine leiomyomas are the most common pelvic neoplasm in women estimated lifetime risk of 70% in white women and 80% in black women [4,5]. Uterine sarcoma is a rare heterogeneous group of tumors of mesenchymal origin, 3 to 7/100,000 in the United States

*Corresponding author: Afaf Semmar, Department of Radiotherapy, National Institute of Oncology, University Mohammed V, Rabat, Morocco, Tel: +22371990282; E-mail: semmar.afaf@gmail.com

Received November 02, 2016; Accepted December 12, 2016; Published December 17, 2016

Citation: Semmar A, Mouden K, Laanaz S, ELallam O, Kabdani T, et al. (2016) Isolated Metastasis of Uterine Leiomyosarcoma to the Small Bowel Diagnosed Initially as Uterine Leiomyoma: A Case Report and Review of the Literature. J Clin Case Rep 6: 901. doi: 10.4172/2165-7920.1000901

Copyright: © 2016 Semmar A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
population, it represents 8% of uterine malignancies. They comprise leiomyosarcoma, endometrial stromal sarcoma, undifferentiated endometrial sarcoma, and Aden sarcoma [6] and has a poor prognosis [7]. Leiomyosarcoma is the most common histological subtype of uterine sarcomas. It may result from a sarcomatous transformation in a benign leiomyoma in 0.2% of cases but the great majority arise de novo [8].

For both leiomyomas and sarcoma, the primary presenting symptoms are abnormal uterine bleeding, pelvic pain or pressure, or a pelvic mass, making the difference between leiomyoma and sarcoma difficult [9-11].

Leiomyosarcoma is the main type of sarcoma that may resemble to leiomyoma. Metastatic neoplasm may be found in women with sarcoma but not with leiomyomas. Uterine sarcomas spread via intra-abdominal, lymphatic, or hematogenous routes. Hematogenous spread is most often to the lungs. Uterine leiomyosarcoma can invade small bowel by direct extension, hematogenous dissemination, implantation, or by lymphatic route [12].

There is no pelvic imaging modality that can reliably differentiate between benign leiomyomas and uterine sarcomas. Leiomyomas and uterine sarcomas appear similar; both are focal masses within the uterus and both can have central necrosis. Pelvic ultrasound followed by MRI is the most useful imaging strategy [13].

Uterine sarcomas is a histologic diagnosis, and they are most commonly diagnosed following surgery for presumed leiomyomas. Anatomopathology criteria to the diagnosis of uterine sarcomas are: mitotic index, cellular atypia, cellularity, mitotic index and geographic areas of coagulative necrosis separated from viable neoplasm. The more features exhibited by the lesion, the more likely it is to have clinically aggressive behavior [14,15].

Leiomyosarcoma of small bowel metastasis from uterine leiomyosarcoma is treated by chemotherapy: doxorubicin alone, gemcitabine alone, or gemcitabine plus docetaxel [16]. Surgical resection is the treatment for lesions confined to the uterus. Small bowel leiomyosarcoma secondary to uterine leiomyosarcoma is a sign of advanced disease with poor prognosis, with a five-year survival rate ranging from 18.8% to 68% [17].

Conclusion

Leiomyosarcoma is the main type of sarcoma that may resemble to leiomyoma. Metastasis to small bowel is rare, treatment is chemotherapy and the prognosis is unfavorable.

References
1. D’angelo E, Prat J (2010) Uterine sarcomas: A review. Gynecol Oncol 116 : 131-139.
2. Gerst PH, Levy J, Swaminathan K, Khshettry V, Albu E (1993) Metastatic leiomyosarcoma of the uterus: unusual presentation of a case with late endobronchial and small bowel metastases. Gynec Oncol 49: 271-275.
3. Ben-Ishay O, Shmuelys V, Brauner E, Vladowsy E, Kluget Y (2010) Mucosal small bowel metastasis from uterine leiomyosarcoma. Israel Med Assoc J 12: 309-310.
4. Baird DD, Dunson DB, Hill MC (2003) High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 188: 100.
5. Serden SP, Brooks PG (1991) Treatment of abnormal uterine bleeding with the gynecologic resectoscope. J Reprod Med 36: 697.
6. Wu TI, Yen TC, Lai CH (2011) Clinical presentation and diagnosis of uterine sarcoma, including imaging. Best Pract Res Clin Obstet Gynaecol 25: 681-689.
7. Brooks SE, Zhan M, Cote T, Baquet CR (2004) Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 93: 204.
8. Sala E, Rockall AG, Freeman SJ, Mitchell DG, Reinhold C (2013) The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: What the radiologist needs to know. Radiology 266: 717-740.
9. Gjontoli RL, Il, Metzinger DS, DiMarco CS (2003) Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 89: 460.
10. Schwartz LB, Diamond MP, Schwartz PE (1993) Leiomyosarcomas: Clinical presentation. Am J Obstet Gynecol 168: 180.
11. Tsikouras P, Liberis V, Galazios G (2008) Uterine sarcoma: A report of 57 cases over a 16-year period analysis, Eur J Gynaecol Oncol 29: 129.
12. Semelka RC, John G, Kelekis NL, Burdery DA, Ascher SM (1996) Small bowel neoplastic disease: Demonstration by MRI. J Magn Reson Imaging 6: 855-860.
13. Amant F, Coosemans A, Debieo-Rychter M (2009) Clinical management of uterine sarcomas. Lancet Oncol, 10: 1188.
14. Bell SW, Kempson RL, Hendrickson MR (1994) Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 18: 535.
15. Quade BJ, Wang TY, Sornberger K (2004) Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer 40: 97.
16. Gupta AA, Yao X, Verma S, Mackay H, Hopkins L (2013) Chemotherapy gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin in inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: A clinical practice guideline. Curr Oncol 20: 448-454.
17. Tse KY, Crawford R, Nyan HYS (2011) Staging of uterine sarcomas. Best Pract Res Clin Obstet Gynaecol 25: 733-749.